Arnon P Kater

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8708113/publications.pdf

Version: 2024-02-01

212	6,237	71102	82547
papers	citations	41 h-index	72 g-index

217	217	217	6882
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Conditional relative survival among patients with chronic lymphocytic leukaemia: A populationâ€based study in the Netherlands. EJHaem, 2022, 3, 180-183.	1.0	3
2	Increasing CART cell engine performance in CLL. Blood, 2022, 139, 473-474.	1.4	2
3	T-cell subset composition and functionality in patients with WaldenstrÃ¶mâ€™s macroglobulinemia. Leukemia and Lymphoma, 2022, , 1-5.	1.3	3
4	Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients. Blood Advances, 2022, 6, 1537-1546.	5.2	45
5	Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations. HemaSphere, 2022, 6, e707.	2.7	17
6	Sodium stibogluconate and CD47-SIRPÎ± blockade overcome resistance of anti-CD20â€“opsonized B cells to neutrophil killing. Blood Advances, 2022, 6, 2156-2166.	5.2	12
7	Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial. Lancet Haematology,the, 2022, 9, e190-e199.	4.6	18
8	Do CARs finally hit the CLL road?. Blood, 2022, 139, 1775-1776.	1.4	1
9	A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies. EJHaem, 2022, 3, 492-506.	1.0	2
10	Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989â€“2018. Blood Cancer Journal, 2022, 12, 72.	6.2	6
11	Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment. Blood, 2022, 140, 630-643.	1.4	14
12	Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas. Cancer Research Communications, 2022, 2, 330-341.	1.7	6
13	Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities. , 2022, 1, .		66
14	Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells. Blood Advances, 2022, 6, 4185-4195.	5.2	6
15	Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110. Leukemia, 2022, , .	7.2	3
16	Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood, 2022, 140, 839-850.	1.4	55
17	Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial. Lancet Oncology, The, 2022, 23, 818-828.	10.7	21
18	Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood Advances, 2022, 6, 4553-4557.	5.2	22

#	Article	IF	Citations
19	Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma. Leukemia, 2022, 36, 2165-2176.	7.2	8
20	Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group. Leukemia and Lymphoma, 2022, 63, 2276-2289.	1.3	3
21	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Blood, 2021, 137, 1365-1376.	1.4	72
22	Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia. Blood, 2021, 137, 1117-1120.	1.4	27
23	A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes VÎ³9VÎ´2 T cellâ€“Mediated Antitumor Responses in Human B-cell Malignancies. Cancer Immunology Research, 2021, 9, 50-61.	3.4	23
24	Human CXCR5⁺PDâ€1⁺ CD8 T cells in healthy individuals and patients with hematologic malignancies. European Journal of Immunology, 2021, 51, 703-713.	2.9	11
25	A Bispecific Single-Domain Antibody Boosts Autologous VÎ³9VÎ´2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2021, 27, 1744-1755.	7.0	28
26	Regulation of Bcl-XL by non-canonical NF-ÎºB in the context of CD40-induced drug resistance in CLL. Cell Death and Differentiation, 2021, 28, 1658-1668.	11.2	41
27	Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19. Blood Advances, 2021, 5, 913-925.	5.2	11
28	T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective. Haematologica, 2021, 106, 1234-1243.	3.5	18
29	Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Journal of Clinical Oncology, 2021, 39, 3441-3452.	1.6	266
30	Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?. Hematology/Oncology Clinics of North America, 2021, 35, 775-791.	2.2	8
31	Poster: CLL-115: First Results of a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S220.	0.4	0
32	Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia. Blood Advances, 2021, 5, 5410-5414.	5.2	20
33	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. Leukemia, 2021, 35, 3444-3454.	7.2	57
34	Targeting Metabolic Alterations in CLL Microenvironment; Inhibition of Glutamine Import Attenuates Venetoclax Resistance. Blood, 2021, 138, 3717-3717.	1.4	0
35	Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial. Blood, 2021, 138, 2639-2639.	1.4	1
36	Time-Limited Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Who Have Undetectable MRD - Primary Analysis from the Randomized Phase II Vision HO141 Trial. Blood, 2021, 138, 69-69.	1.4	3

#	Article	IF	Citations
37	Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial. Blood, 2021, 138, 2627-2627.	1.4	6
38	Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL). Blood, 2021, 138, 3721-3721.	1.4	0
39	High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial. Blood, 2021, 138, 72-72.	1.4	3
40	For Better or for Worse: COVID-19 Vaccination during or Early after (Immuno-) Chemotherapy or Hematopoietic Progenitor Cell Transplantation. Blood, 2021, 138, 754-754.	1.4	0
41	Bispecific VÎ³9VÎ´2-T and Type 1 NKT Cell Engager Lava-051 As First-in-Class Clinical Candidate to Target CD1d Expressing CLL, MM and AML. Blood, 2021, 138, 2266-2266.	1.4	0
42	Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx). Blood, 2021, 138, 1548-1548.	1.4	5
43	Chronic Lymphocytic Leukemia (CLL) Clonal Growth Rate Is Slower Following Venetoclax-Rituximab (VenR): Results from a Minimal Residual Disease (MRD) Model from the Randomized Phase 3 Murano Trial. Blood, 2021, 138, 1551-1551.	1.4	0
44	First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study. Blood, 2021, 138, 70-70.	1.4	20
45	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. Blood, 2021, 138, 2635-2635.	1.4	1
46	Ibrutinib Treatment in CLL Interrupts CD40 Signaling Capacity and Sensitizes CLL Cells to Venetoclax. Blood, 2021, 138, 1545-1545.	1.4	3
47	Chronic Lymphocytic Leukemia Actively Induces T-Cell Dysfunction By Contact-Dependent Signaling Via CD24 and CD52. Blood, 2021, 138, 3714-3714.	1.4	1
48	A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial. Blood, 2021, 138, 71-71.	1.4	36
49	Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features. Frontiers in Oncology, 2021, 11, 780085.	2.8	4
50	Exposureâ€“response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study. Leukemia and Lymphoma, 2020, 61, 56-65.	1.3	7
51	Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. Journal of Clinical Oncology, 2020, 38, 4042-4054.	1.6	141
52	Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study. Experimental Hematology, 2020, 89, 55-60.e6.	0.4	2
53	Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib. Leukemia and Lymphoma, 2020, 61, 3422-3431.	1.3	1
54	Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. Cancers, 2020, 12, 3837.	3.7	9

#	Article	IF	Citations
55	Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?. Frontiers in Oncology, 2020, 10, 592205.	2.8	31
56	Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance â‰¥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations. BMJ Open, 2020, 10, e039168.	1.9	7
57	Glucoseâ€6â€phosphate dehydrogenase deficiencyâ€associated hemolysis and methemoglobinemia in a <scp>COVID</scp>â€19 patient treated with chloroquine. American Journal of Hematology, 2020, 95, E194-E196.	4.1	20
58	CAR-T and ibrutinib vs CLL: sequential or simultaneous?. Blood, 2020, 135, 1611-1612.	1.4	6
59	Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia. Annals of Hematology, 2020, 99, 1081-1091.	1.8	0
60	CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells. , 2020, 8, e000218.		19
61	Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood, 2020, 136, 2918-2926.	1.4	67
62	COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia, 2020, 34, 2225-2229.	7.2	39
63	Response in patients with BIRC3-mutated relapsed/refractory chronic lymphocytic leukemia treated with fixed-duration venetoclax and rituximab. Haematologica, 2020, 105, e382-e383.	3.5	6
64	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia, 2020, 34, 2354-2363.	7.2	198
65	Functional Differences Between EBVâ€•and CMVâ€Specific CD8⁺ T cells Demonstrate Heterogeneity of T cell Dysfunction in CLL. HemaSphere, 2020, 4, e337.	2.7	3
66	The Effect of SF3B1 Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer. Frontiers in Oncology, 2020, 10, 609409.	2.8	15
67	Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study. Blood, 2020, 136, 44-45.	1.4	15
68	Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. Haematologica, 2020, 106, 87-97.	3.5	43
69	Neutropenia analysis of venetoclax monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: Pooled data from VENICE-I and -II Phase IIIb trials.. Journal of Clinical Oncology, 2020, 38, e20011-e20011.	1.6	0
70	Development of a Novel Lymph Node-Based 3D Culture System Promoting Chronic Lymphocytic Leukemia Proliferation and Survival. Blood, 2020, 136, 47-48.	1.4	0
71	Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study. Blood, 2020, 136, 38-39.	1.4	5
72	Electron Transport Chain Inhibition Suppresses CD40 Expression and Sensitizes Chronic Lymphocytic Leukaemia Cells to Venetoclax. Blood, 2020, 136, 35-35.	1.4	0

#	Article	IF	Citations
73	Effects of Ibrutinib on Metabolic Alterations and Micro-Environmental Signalling in Chronic Lymphocytic Leukaemia. Blood, 2020, 136, 36-37.	1.4	1
74	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. Blood, 2020, 136, 45-49.	1.4	2
75	Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. Leukemia, 2019, 33, 390-402.	7.2	44
76	Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia. Haematologica, 2019, 104, 147-154.	3.5	10
77	Ibrutinib and Venetoclax for First-Line Treatment of CLL. New England Journal of Medicine, 2019, 381, 788-789.	27.0	11
78	Ibrutinibâ€associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and nonâ€Hodgkin lymphoma: An observational study. Mycoses, 2019, 62, 1140-1147.	4.0	57
79	Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences, 2019, 20, 4315.	4.1	21
80	Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes. Journal of Immunology, 2019, 203, 2100-2109.	0.8	16
81	Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia, 2019, 33, 2762-2766.	7.2	67
82	Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study. Clinical Pharmacokinetics, 2019, 58, 1621-1634.	3.5	10
83	Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy. Blood, 2019, 134, 44-58.	1.4	118
84	Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. Journal of Clinical Oncology, 2019, 37, 269-277.	1.6	250
85	Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. Blood Advances, 2019, 3, 2642-2652.	5.2	79
86	Rare but Serious: Ibrutinib Induced Liver Failure. HemaSphere, 2019, 3, e307.	2.7	5
87	Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?. HemaSphere, 2019, 3, 44-46.	2.7	0
88	Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood, 2019, 133, 1205-1216.	1.4	164
89	Ibrutinib: searching for a partner drug. Lancet Oncology, The, 2019, 20, 3-5.	10.7	6
90	Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling. HemaSphere, 2019, 3, e308.	2.7	14

#	Article	IF	Citations
91	PreVent-ACaLL Short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment, who do not fulfil IWCLL treatment criteria for treatment. A randomized study with extensive immune phenotyping. Blood, 2019, 134, 4304-4304.	1.4	10
92	A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation. Blood, 2019, 134, 4318-4318.	1.4	9
93	Combined Ibrutinib and Venetoclax Changes Myeloid Phenotype and Improves Immune Function in CLL Patients. Blood, 2019, 134, 4289-4289.	1.4	2
94	Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial. Blood, 2019, 134, 356-356.	1.4	1
95	Four-Year Analysis of Murano Study Confirms Sustained Benefit of Time-Limited Venetoclax-Rituximab (VenR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood, 2019, 134, 355-355.	1.4	16
96	Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 HO141 Trial. Blood, 2019, 134, 4292-4292.	1.4	4
97	First Line Treatment with Venetoclax and Ibrutinib Induction Followed By Obinutuzumab Intensification Exclusively in CLL/SLL Patients Not in Complete Remission and/or with Detectable Bone Marrow Minimal Residual Disease (NEXT STEP trial). Blood, 2019, 134, 1753-1753.	1.4	2
98	Cross-Talk between Cytokine and NF-Ä¸b Signaling in the CLL Microenvironment Can Affect Sensitivity for Venetoclax. Blood, 2019, 134, 5449-5449.	1.4	0
99	CD3xCD19 Dart Treatment Is Efficient in Venetoclax Resistant CLL and Reverses T Cell Dysfunction. Blood, 2019, 134, 3043-3043.	1.4	0
100	Linking Microenvironmental Signals to Metabolic Switches and Drug Responses in Chronic Lymphocytic Leukemia. Blood, 2019, 134, 479-479.	1.4	1
101	Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. Lancet Haematology,the, 2018, 5, e170-e180.	4.6	44
102	Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy. Leukemia and Lymphoma, 2018, 59, 2757-2761.	1.3	1
103	Final results of a phase 1b study of the safety and efficacy of the PI3KÎ´ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies. Blood Cancer Journal, 2018, 8, 16.	6.2	19
104	Relative survival reaches a plateau in hairy cell leukemia: a population-based analysis in The Netherlands. Blood, 2018, 131, 1380-1383.	1.4	22
105	Venetoclaxâ€“Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2018, 378, 1107-1120.	27.0	684
106	Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 52-57.	0.4	7
107	Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet, The, 2018, 391, 659-667.	13.7	324
108	Improving CLL VÎ³9VÎ´2-Tâ€“cell fitness for cellular therapy by ex vivo activation and ibrutinib. Blood, 2018, 132, 2260-2272.	1.4	39

#	Article	IF	Citations
109	Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL. Blood Advances, 2018, 2, 3566-3571.	5.2	22
110	Venetoclaxâ€“Rituximab in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2018, 378, 2141-2144.	27.0	12
111	Autoimmune cytopenias in chronic lymphocytic leukemia: a concise review and treatment recommendations. Expert Review of Hematology, 2018, 11, 613-624.	2.2	24
112	MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood, 2018, 132, 184-184.	1.4	8
113	Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma. Blood, 2018, 132, 2876-2876.	1.4	14
114	Chronic Lymphocytic Leukemia Cells Impair Mitochondrial Fitness in CD8+ T Cells and Impede CAR T Cell Efficacy. Blood, 2018, 132, 235-235.	1.4	2
115	First Evidence of Restoration of T and NK Cell Compartment after Venetoclax Treatment. Blood, 2018, 132, 1860-1860.	1.4	5
116	First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study. Blood, 2018, 132, 185-185.	1.4	2
117	The GAIA (CLL13) trial: An international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology, 2018, 36, TPS7582-TPS7582.	1.6	7
118	A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.. Journal of Clinical Oncology, 2018, 36, TPS7588-TPS7588.	1.6	6
119	B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide.. Journal of Clinical Oncology, 2018, 36, 7531-7531.	1.6	0
120	A New Therapeutic Hypothesis: Nonsense-Mediated Decay Is an Exploitable Target in Multiple Myeloma. Blood, 2018, 132, 1937-1937.	1.4	0
121	First Evidence of Dysfunctional Antigen-Specific T Cell Responses in Experimental CLL As a Model for Studies of Autologous T Cell-Based Therapies. Blood, 2018, 132, 3694-3694.	1.4	0
122	CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis. Haematologica, 2017, 102, 2069-2076.	3.5	11
123	Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematology,the, 2017, 4, e475-e486.	4.6	45
124	Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk. Haematologica, 2017, 102, 1469-1476.	3.5	52
125	Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach. Haematologica, 2017, 102, 1629-1639.	3.5	111
126	Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection. Journal of Hepatology, 2017, 66, 242-243.	3.7	65

#	Article	IF	Citations
127	Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling. Oncotarget, 2017, 8, 71981-71995.	1.8	27
128	Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study. Blood, 2017, 130, LBA-2-LBA-2.	1.4	14
129	'Trained immunity: consequences for lymphoid malignancies. Haematologica, 2016, 101, 1460-1468.	3.5	21
130	Innate lymphoid cells are expanded and functionally altered in chronic lymphocytic leukemia. Haematologica, 2016, 101, e461-e464.	3.5	47
131	Chronic lymphocytic leukemia development is accelerated in mice with deficiency of the pro-apoptotic regulator NOXA. Haematologica, 2016, 101, e374-e377.	3.5	6
132	Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. Blood, 2016, 128, 574-583.	1.4	69
133	Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia. Journal of Immunology, 2016, 197, 2532-2540.	0.8	110
134	TP53 dysfunction in CLL: Implications for prognosis and treatment. Best Practice and Research in Clinical Haematology, 2016, 29, 90-99.	1.7	14
135	Bcl-2 Members As Drug Target and Biomarkers for Response to Ibrutinib and Venetoclax in CLL. Blood, 2016, 128, 2043-2043.	1.4	3
136	Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group). Blood, 2016, 128, 229-229.	1.4	12
137	Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites. Blood, 2016, 128, 4376-4376.	1.4	1
138	Impaired Metabolic Fitness in T Cells in Chronic Lymphocytic Leukemia. Blood, 2016, 128, 2528-2528.	1.4	1
139	Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica, 2015, 100, e302-6.	3.5	100
140	Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. Blood, 2015, 125, 2306-2309.	1.4	79
141	PD-L1 blockade: rejuvenating T cells in CLL. Blood, 2015, 126, 126-128.	1.4	9
142	The 8th Young Investigatorsâ€™ Meeting on Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 2015, 56, 1556-1559.	1.3	1
143	Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia. Leukemia and Lymphoma, 2015, 56, 2439-2447.	1.3	6
144	The T-Cell/CLL/Macrophage Triad Shapes a Supportive Tumor Microenvironment in CLL. Blood, 2015, 126, 1715-1715.	1.4	3

#	Article	IF	Citations
145	Chronic Lymphocytic Leukemia (CLL) Cells Are Susceptible to Î³Î´-T Cell Mediated Killing, Provided CLL-Derived Î³Î´-T Cell Dysfunction Can be Reversed. Blood, 2015, 126, 2914-2914.	1.4	3
146	Exome-Wide Sequencing Reveals Oncogenic Mutations in Both Progressive and Non-Progressive MBL. Blood, 2015, 126, 361-361.	1.4	0
147	Targeting BCR-Independent Proliferation of CLL Cells. Blood, 2015, 126, 2916-2916.	1.4	0
148	CLL Disease Severity Is Enhanced in Tcl1 Mice Deficient for Pro-Apoptotic Regulator Noxa. Blood, 2015, 126, 4144-4144.	1.4	0
149	EBV-Specific CD8+ T-Cells Are Not Functionally Impaired in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 1723-1723.	1.4	16
150	Assessment of <scp>TP</scp>53 functionality in chronic lymphocytic leukaemia by different assays; an <scp>ERIC</scp>â€wide approach. British Journal of Haematology, 2014, 167, 565-569.	2.5	7
151	Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: A multicenter phase 2 study. Leukemia Research, 2014, 38, 34-41.	0.8	24
152	CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia. Blood, 2014, 123, 717-724.	1.4	53
153	miR in CLL: more than mere markers of prognosis?. Blood, 2014, 124, 2-4.	1.4	0
154	How does lenalidomide target the chronic lymphocytic leukemia microenvironment?. Blood, 2014, 124, 2184-2189.	1.4	60
155	Combined Inhibition of mTOR and DNA-PK Blocks Survival, Adhesion, Proliferation and Chemoresistance in Primary Chronic Lymphocytic Leukemia (CLL) Cells. Blood, 2014, 124, 1981-1981.	1.4	3
156	Good Tolerance of Lenalidomide Maintenance Therapy in Patients with High Risk Profile Chronic Lymphocytic Leukemia (CLL) after Frontline Chemoimmunotherapy: Preliminary Safety Overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG). Blood, 2014, 124, 4699-4699.	1.4	2
157	A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study. Blood, 2014, 124, 1976-1976.	1.4	2
158	Combined Inhibition of Phosphatidylinositol 3-Kinase (PI3K) Isoform Î± and Î´ By the Pan-Class I PI3K Inhibitor SAR245409 (XL765) in Primary Chronic Lymphocytic Leukemia Cells Blocks Survival, Adhesion and Proliferation. Blood, 2014, 124, 4691-4691.	1.4	1
159	IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. Blood, 2013, 122, 3010-3019.	1.4	107
160	Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia. British Journal of Haematology, 2013, 163, 496-500.	2.5	42
161	The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia. Leukemia Research, 2013, 37, 838-847.	0.8	5
162	Overview of available p53 function tests in relation toTP53andATMgene alterations and chemoresistance in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 1849-1853.	1.3	15

#	Article	IF	Citations
163	A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. Journal of Experimental Medicine, 2013, 210, 59-70.	8.5	132
164	The Impact Of Subclonal Versus Clonal Novel Recurrent Mutations On Treatment Outcome In Previously Untreated High Risk CLL Patients: Results From The HOVON68 Trial. Blood, 2013, 122, 2861-2861.	1.4	1
165	Interim Analysis Of Dose-Escalation Stage Of a Phase 1b Study Evaluating Safety and Pharmacology Of GS-9820, a Second-Generation, Selective, PI3Kd-Inhibitor in Recurrent Lymphoid Malignancies. Blood, 2013, 122, 2881-2881.	1.4	7
166	Possible Mechanisms Of Resistance To The Novel BH3-Mimetic ABT-199 In In Vitro Lymph Node Models Of CLL â€“ The Role Of Abl and Btk. Blood, 2013, 122, 4188-4188.	1.4	6
167	R-DHAP Immunochemotherapy Is An Effective Remission-Induction Treatment For CLL Patients With Fludarabine Refractory Disease With Or Without Deletion 17p, Enabling The Majority To Proceed To Allogeneic Stem Cell Transplantation. Blood, 2013, 122, 2883-2883.	1.4	0
168	CMV-Specific CD8+ T-CELL Function Is NOT Impaired In CLL. Blood, 2013, 122, 2862-2862.	1.4	0
169	Next-Generation Sequencing Reveals Oncogenic Driver Mutations In Both Progressive and Non-Progressive Monoclonal B Lymphocytosis. Blood, 2013, 122, 1615-1615.	1.4	0
170	Highlights of the 6th Young Investigatorsâ€™ Meeting on chronic lymphocytic leukemia. Leukemia and Lymphoma, 2012, 53, 2312-2313.	1.3	0
171	Chronic lymphocytic leukemia specific T-cell subset alterations are clone-size dependent and not present in monoclonal B lymphocytosis. Leukemia and Lymphoma, 2012, 53, 2321-2325.	1.3	12
172	Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia. Leukemia and Lymphoma, 2012, 53, 1785-1794.	1.3	30
173	Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2012, 18, 487-498.	7.0	88
174	Assessment of p53 Functionality in Chronic Lymphocytic Leukemia by Different Assays; An Eric-Wide Approach.. Blood, 2012, 120, 2872-2872.	1.4	1
175	SF3B1 Mutations in CLL Are Equivalent to p53/ATM Dysfunction and Cause Defective Puma Upregulation in Response to Chemotherapy. Blood, 2012, 120, 711-711.	1.4	5
176	The Broad Kinase Inhibitor Dasatinib in Combination with Fludarabine in Patients with Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase 2 Study. Blood, 2012, 120, 1798-1798.	1.4	1
177	Mapping the Targets of Dasatinib in Chronic Lymphocytic Leukemia Reveals Distinct Roles for Abl and Btk in Drug Resistance and Adhesion, and Explains Clinical Effects On Lymph Node Reduction. Blood, 2012, 120, 3900-3900.	1.4	2
178	Waxing and waning intravascular large cell lymphoma with widespread organ infiltration. Leukemia and Lymphoma, 2011, 52, 705-708.	1.3	4
179	DNA damageâ€“induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. Blood, 2011, 117, 1622-1632.	1.4	35
180	Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas. Blood, 2011, 117, 6856-6865.	1.4	47

#	Article	IF	Citations
181	Use of the CD19 count in a primary care laboratory as a screening method for B-cell chronic lymphoproliferative disorders in asymptomatic patients with lymphocytosis. Clinical Chemistry and Laboratory Medicine, 2011, 49, 115-20.	2.3	7
182	Identification of a Novel B-CLL Subset Expressing Mutated Stereotyped B-Cell Receptors with Specificity for Yeast Mannan. Blood, 2011, 118, 623-623.	1.4	1
183	Role of T Cell-Derived IL-21 in the Proliferation of Chronic Lymphocytic Leukemia Cells,. Blood, 2011, 118, 3871-3871.	1.4	0
184	B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18956-18960.	7.1	64
185	Standards for the Treatment of Relapsed Chronic Lymphocytic Leukemia: A Case-Based Study. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, S34-S41.	0.4	2
186	miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood, 2009, 113, 3801-3808.	1.4	258
187	B Cell Activating Factor and c-Myc Regulate the Progression of Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 359-359.	1.4	1
188	R-DHAP Is Effective in Fludarabine-Refractory CLL, Possibly Via Upregulation of Pro-Apoptotic P73.. Blood, 2009, 114, 3449-3449.	1.4	0
189	ROS-Mediated Upregulation of Noxa Overcomes Drug-Resistance Due to P53-Dysfunction in Chronic Lymphocytic Leukemia.. Blood, 2009, 114, 2382-2382.	1.4	0
190	Invasive infections with a coagulase-negative staphylococcus in an immunocompromised patient: case report and review of the literature. Annals of Hematology, 2008, 87, 771-772.	1.8	9
191	In vivo Dynamics of Stable Chronic Lymphocytic Leukemia Inversely Correlate with Somatic Hypermutation Levels and Suggest No Major Leukemic Turnover in Bone Marrow. Cancer Research, 2008, 68, 10137-10144.	0.9	52
192	Poor Outcomes of Chronic Active Epsteinâ€Barr Virus Infection and Hemophagocytic Lymphohistiocytosis in Nonâ€Japanese Adult Patients. Clinical Infectious Diseases, 2008, 47, 105-108.	5.8	42
193	c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood, 2008, 112, 5141-5149.	1.4	107
194	Mir-34a as Part of the Chemotherapy Resistance Network in Chronic Lymphocytic Leukemia.. Blood, 2008, 112, 1209-1209.	1.4	1
195	Platinum-Based Compounds Induce Expression of p73 and Restores Drug- Sensitivity in p53 Dysfunctional Chronic Lymphocytic Leukemia (CLL) Cells.. Blood, 2008, 112, 2102-2102.	1.4	0
196	Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood, 2007, 109, 1660-1668.	1.4	147
197	Cellular immune therapy for chronic lymphocytic leukemia. Blood, 2007, 110, 2811-2818.	1.4	29
198	The Role of DNA and Actin Polymers on the Polymer Structure and Rheology of Cystic Fibrosis Sputum and Depolymerization by Gelsolin or Thymosin Beta 4. Annals of the New York Academy of Sciences, 2007, 1112, 140-153.	3.8	43

#	Article	IF	Citations
199	c-Abl Kinase Inhibitors Overcome CD40-Mediated Drug Resistance in CLL.. Blood, 2007, 110, 3078-3078.	1.4	2
200	In Vivo Tumor Dynamic Studies in Stable CLL Show an Association between CLL Turnover Rates and IgVH Mutational Status and Provide Evidence That the Bone Marrow Is Not a Major Site of Neoplastic Cell Generation.. Blood, 2007, 110, 1128-1128.	1.4	0
201	CD31-CD38 Interaction Has No Major Role in the Pathogenesis of CLL.. Blood, 2007, 110, 1139-1139.	1.4	0
202	Thymosin Î²4 Sequesters Actin in Cystic Fibrosis Sputum and Decreases Sputum Cohesivity in Vitro. Chest, 2006, 130, 1433-1440.	0.8	27
203	Increased Expression Level of Noxa in Peripheral Versus Lymph Node Chronic Lymphocytic Leukemia Cells Is Correlated with Survival Capacity.. Blood, 2006, 108, 4972-4972.	1.4	0
204	Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells. Blood, 2005, 105, 3193-3198.	1.4	55
205	Autologous cytomegalovirus-specific T cells as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia. British Journal of Haematology, 2004, 126, 512-516.	2.5	12
206	CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. British Journal of Haematology, 2004, 127, 404-415.	2.5	65
207	CD40-Activation of Chronic Lymphocytic Leukemia Cells Induces Latent Sensitivity to Fas/TRAIL-Mediated Apoptosis Via a P53-Independent, C-Abl-Dependent Pathway.. Blood, 2004, 104, 342-342.	1.4	1
208	Inhibition of XIAP Enhances Specific Cytotoxic T Lymphocyte (CTL) Killing and CD20-Directed Antibody-Dependent Cellular Cytotoxicity of Chronic Lymphocytic Leukemia B Cells.. Blood, 2004, 104, 3475-3475.	1.4	1
209	Inhibition of XIAP Renders Newly CD40-Activated Chronic Lymphocytic Leukemia Cells Sensitive to Fas (CD95) Mediated Apoptosis.. Blood, 2004, 104, 3474-3474.	1.4	0
210	Autologous CMV-Specific T Cells as Effector Cells in Immunotherapy of B Cell Chronic Lymphocytic Leukemia.. Blood, 2004, 104, 2512-2512.	1.4	0
211	Chronic Lymphocytic Leukemia Cells May Become Less Dependent on Nurse-Like Cells during Later Stages of Disease.. Blood, 2004, 104, 4805-4805.	1.4	0
212	Dichotomal Effect of the Coumadin Derivative Warfarin on Inflammatory Signal Transduction. Vaccine Journal, 2002, 9, 1396-1397.	3.1	19